更适合的KL-VS异构体具有更有利的AD相关生物标志物概况
Mackenzie Jarchow1, Ira Driscoll1,2, Brianne M Breidenbach1,2
1Wisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Alzheimer's & dementia (New York, N. Y.)
|August 11, 2025
概括
更高的心肺呼吸能力 (CRF) 和KLOTHO基因变异KL-VSHET协同保护阿尔茨海默病 (AD) 生物标志物. 这种组合降低了tau,神经素,sTREM2和YKL-40的水平,表明对AD相关变化的保护作用.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 心脏病学 心脏病学
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样斑块和神经纤维状,但也涉及神经炎症,神经退行和突触功能障碍.
- 克洛托基因变异KL-VSHET和心肺健康 (CRF) 独立地与减弱的AD病理学有关.
- 这项研究研究了KL-VSHET和CRF对AD生物标志物的联合作用.
研究的目的:
- 为了检查CRF (高峰氧气消耗,VO2peak) 和KLOTHO基因型 (KL-VSHET与KL-VSNC) 在脑脊液 (CSF) 的AD生物标志物之间的相互作用.
- 评估对AD核心病理,神经炎症,神经退行和突触功能障碍标记物的影响.
- 为了确定KL-VSHET和更高的CRF之间是否存在协同保护作用.
主要方法:
- 对136名具有AD风险较高的认知正常成年人进行分析.
- 调整为共变量 (年龄,性别,AD史,APOE ε4状态) 的线性模型检查了VO2峰和KLOTHO基因型之间的相互作用.
- 测量到的CSF生物标志物包括核心AD标志物 (pTau181,Aβ42/Aβ40),神经退行性标志物 (tTau,NfL),突触功能障碍标志物 (Ng) 和神经炎症标志物 (GFAP,sTREM2,YKL-40,IL-6,S100B).
主要成果:
- 在tTau,pTau181,Ng,sTREM2和YKL-40 (p <0.05) 中发现了VO2峰和KL-VSHET之间的显著相互作用.
- 患有KL-VSHET和较高CRF的个体表现出这些特定生物标志物的较低水平.
- 对Aβ42/Aβ40,pTau181/Aβ42,α-syn,NfL,GFAP,IL-6或S100B没有观察到显著的相互作用.
结论:
- 在KLOTHO KL-VSHET变种和CRF之间存在与特定AD生物标志物相关的协同关系.
- 无论是KL-VSHET还是更高的CRF,似乎都提供了对不良AD相关变化的保护作用.
- 需要进一步的研究来阐明这些保护作用背后的共享生物机制.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
978
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
相关概念视频
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
